ATE478872T1 - Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung - Google Patents
Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendungInfo
- Publication number
- ATE478872T1 ATE478872T1 AT02007163T AT02007163T ATE478872T1 AT E478872 T1 ATE478872 T1 AT E478872T1 AT 02007163 T AT02007163 T AT 02007163T AT 02007163 T AT02007163 T AT 02007163T AT E478872 T1 ATE478872 T1 AT E478872T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- group
- cycloalkyl
- optionally substituted
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02007163A EP1348707B1 (de) | 2002-03-28 | 2002-03-28 | Pyrazolo[4,3-d]pyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE478872T1 true ATE478872T1 (de) | 2010-09-15 |
Family
ID=27798825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02007163T ATE478872T1 (de) | 2002-03-28 | 2002-03-28 | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung |
Country Status (9)
Country | Link |
---|---|
US (1) | US7745450B2 (de) |
EP (1) | EP1348707B1 (de) |
JP (1) | JP2005527565A (de) |
AT (1) | ATE478872T1 (de) |
AU (1) | AU2003226731B2 (de) |
CA (1) | CA2480409C (de) |
DE (1) | DE60237425D1 (de) |
DK (1) | DK1348707T3 (de) |
WO (1) | WO2003082872A1 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
WO2004096810A1 (en) | 2003-04-29 | 2004-11-11 | Pfizer Limited | 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension |
WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
GB0327319D0 (en) * | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
RU2006126791A (ru) * | 2003-12-23 | 2008-01-27 | Новартис АГ (CH) | Бициклические гетероциклические ингибиторы р-38 киназы |
DE602005011784D1 (de) | 2004-04-07 | 2009-01-29 | Pfizer | Pyrazoloä4,3-düpyrimidine |
GEP20105024B (en) * | 2004-06-02 | 2010-06-25 | Takeda Pharmaceuticals Co | Fused heterocyclic compound |
EP1797096B1 (de) | 2004-09-06 | 2011-07-27 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidine als hemmer der proteinkinase b (akt) |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
ATE493413T1 (de) * | 2005-05-12 | 2011-01-15 | Pfizer | Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3- |
AU2006272876A1 (en) | 2005-07-22 | 2007-02-01 | Sunesis Pharmaceuticals, Inc. | Pyrazolo pyrimidines useful as aurora kinase inhibitors |
NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
KR20090090336A (ko) | 2006-12-12 | 2009-08-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합된 헤테로시클릭 화합물 |
US20090099195A1 (en) * | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
AU2009311756B2 (en) | 2008-11-06 | 2012-05-03 | Astrazeneca Ab | Modulators of amyloid beta. |
CZ302711B6 (cs) * | 2009-06-03 | 2011-09-14 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující |
CZ2009358A3 (cs) * | 2009-06-03 | 2010-12-15 | C3 Bio Gmbh | 5,7-Disubstituované 3-isopropylpyrazolo[4,3-d]pyrimidiny pro použití jako lécivo a farmaceutické prípravky tyto látky obsahující |
SG194549A1 (en) | 2011-04-21 | 2013-12-30 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
LT2734186T (lt) | 2011-07-22 | 2018-12-10 | Glaxosmithkline Llc | Kompozicija |
AR090650A1 (es) * | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
UY34987A (es) | 2012-08-24 | 2014-03-31 | Glaxosmithkline Llc | ?nuevos compuestos inductores del interferón humano para el tratamiento de diversos trastornos? |
WO2014060112A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
RS56233B1 (sr) | 2012-11-20 | 2017-11-30 | Glaxosmithkline Llc | Nova jedinjenja |
ES2625023T3 (es) | 2012-11-20 | 2017-07-18 | Glaxosmithkline Llc | Compuestos novedosos |
US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
CN103405439B (zh) * | 2013-08-02 | 2014-12-31 | 上海市第十人民医院 | 嘧啶类化合物在制备真菌药物的应用 |
AU2016232987A1 (en) * | 2015-03-16 | 2017-11-02 | Monash University | Treatment of skin conditions |
CZ307147B6 (cs) * | 2015-05-14 | 2018-02-07 | Ústav experimentální botaniky AV ČR, v. v. i. | 5-Substituované 7-[4-(2-pyridyl)fenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako léčiva, a farmaceutické přípravky |
CA3037748A1 (en) * | 2016-09-30 | 2018-04-05 | Asana Biosciences, Llc | P2x3 and/or p2x2/3 compounds and methods |
CZ308484B6 (cs) | 2018-02-05 | 2020-09-16 | Univerzita PalackĂ©ho v Olomouci | 5-Alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidiny pro léčení lymfomů |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3988338A (en) * | 1974-04-24 | 1976-10-26 | Wisconsin Alumni Research Foundation | 4-Substituted amino-2-substituted thio-pyrrolo-[2,3-d]pyrimidine derivatives |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
US5276143A (en) | 1990-12-21 | 1994-01-04 | E. I. Du Pont De Nemours And Company | Dideoxyfructonucleosides and deoxyfructonucleotides |
US5801015A (en) | 1995-06-05 | 1998-09-01 | Mitotix, Inc. | Nucleic acid encoding a Candida cell cycle regulatory protein, TYP1 polypeptide |
US6200980B1 (en) | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
ATE243697T1 (de) * | 1995-12-08 | 2003-07-15 | Pfizer | Substitutierte heterozyclische derivate als crf antagonisten |
DE69736711T2 (de) * | 1996-08-28 | 2007-09-20 | Pfizer Inc. | Substituierte 6,5-heterobicyclische-derivate |
US5723608A (en) * | 1996-12-31 | 1998-03-03 | Neurogen Corporation | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
ID22834A (id) * | 1997-04-25 | 1999-12-09 | Pfizer | Pirazolopimidinona untuk kelainan seksual |
US5985848A (en) * | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
DK1073658T3 (da) * | 1998-04-20 | 2003-12-08 | Pfizer | Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse |
WO2000024745A1 (en) * | 1998-10-23 | 2000-05-04 | Pfizer Limited | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
WO2001019827A1 (en) * | 1999-09-13 | 2001-03-22 | Cipla Ltd. | A novel process for the synthesis of sildenafil citrate |
JP2003513888A (ja) * | 1999-10-12 | 2003-04-15 | ユルグ ラレイダ | 神経疾患治療用医薬品 |
DE10060388A1 (de) * | 2000-12-05 | 2002-06-06 | Merck Patent Gmbh | Verwendung von Pyrazolo [4,3-d]pyrimidinen |
PL362513A1 (en) * | 2000-12-19 | 2004-11-02 | Merck Patent Gmbh | Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
GB0106661D0 (en) * | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
KR20040053210A (ko) * | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
-
2002
- 2002-03-28 EP EP02007163A patent/EP1348707B1/de not_active Expired - Lifetime
- 2002-03-28 DE DE60237425T patent/DE60237425D1/de not_active Expired - Lifetime
- 2002-03-28 AT AT02007163T patent/ATE478872T1/de not_active IP Right Cessation
- 2002-03-28 DK DK02007163.5T patent/DK1348707T3/da active
-
2003
- 2003-03-27 CA CA2480409A patent/CA2480409C/en not_active Expired - Fee Related
- 2003-03-27 AU AU2003226731A patent/AU2003226731B2/en not_active Ceased
- 2003-03-27 JP JP2003580337A patent/JP2005527565A/ja active Pending
- 2003-03-27 WO PCT/EP2003/003207 patent/WO2003082872A1/en active Application Filing
-
2004
- 2004-09-28 US US10/952,087 patent/US7745450B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1348707A1 (de) | 2003-10-01 |
DE60237425D1 (de) | 2010-10-07 |
AU2003226731A1 (en) | 2003-10-13 |
DK1348707T3 (da) | 2010-12-13 |
WO2003082872A1 (en) | 2003-10-09 |
JP2005527565A (ja) | 2005-09-15 |
CA2480409A1 (en) | 2003-10-09 |
CA2480409C (en) | 2010-06-22 |
US20050080097A1 (en) | 2005-04-14 |
EP1348707B1 (de) | 2010-08-25 |
AU2003226731B2 (en) | 2008-05-22 |
US7745450B2 (en) | 2010-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE478872T1 (de) | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung | |
CA2184919A1 (en) | New Piperazine Derivatives and Methods for the Preparation Thereof and Compositions Containing the Same | |
WO2003076458A3 (en) | Selective dipeptide inhibitors of kallikrein | |
WO2005092858A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist | |
CA2337041A1 (en) | Aminomethylcarboxylic acid derivatives | |
HUP0402507A2 (hu) | N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények | |
MXPA06001274A (es) | Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio. | |
HUP0301671A2 (hu) | 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk | |
DE69528437D1 (de) | Substituierte azaindolylidenderivate und verfahren zu ihrer herstellung | |
SE0104332D0 (sv) | Therapeutic agents | |
MY141504A (en) | Gamma secretase inhibitors | |
PT1159279E (pt) | 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais | |
CA2368413A1 (en) | Derivatives of pyrimido[6,1-a]isoquinolin-4-one | |
TW368501B (en) | 7-(2-aminoethyl)-benzothiazolones | |
EP2289888A3 (de) | Epoxidcarboxylsäureamide, Azide und Aminoalkohole sowie Verfahren zur Herstellung von Alpha-Ketoamiden damit | |
MX9706394A (es) | Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1. | |
ES2191341T3 (es) | Derivados de la 2-fenoxianilina. | |
TW200420559A (en) | Amine compounds and method for producing the same | |
AR023914A1 (es) | Caprolactamas sustituidas, un proceso para su preparacion, composiciones farmaceuticas que las contienen, y su uso para la preparacion de composicionesfarmaceuticas en el tratamiento de tumores | |
EP0431520A3 (en) | Heterocyclic acyl aminodiol beta-amino acid derivatives | |
DE50202381D1 (de) | Geschützte tyrosinderivate, verfahren zu deren herstellung und deren verwendung zur herstellung von o-(2- ?18 f]-fluorethyl)-l-tyrosin | |
GB0113232D0 (en) | Chemical process | |
DE3787030T2 (de) | 1-carboxy-1-vinyloxyiminoaminothiazol-cephalosporin-derivate und deren herstellung. | |
MXPA01009768A (es) | Analogos de fenoxazina utiles como inhibidores de la agregacion amiloide y para el tratamiento de la enfermedad de alzheimer y las enfermedades relacionadas con la amiloidosis. | |
WO2003043582A3 (en) | Modulators of rho c activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |